Advances in rheumatoid arthritis

被引：39

作者：

Jones, Graeme ^{[1
]}

Nash, Peter ^{[2
]}

Hall, Stephen ^{[3
]}

机构：

[1] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia

[2] Coast Joint Care, Maroochydore, Qld, Australia

[3] Cabrini Med Ctr, Malvern, Vic, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2017年 / 206卷 / 05期

基金：

英国医学研究理事会;

关键词：

SERIOUS INFECTION; DOUBLE-BLIND; METHOTREXATE; THERAPY; DISEASE; TOCILIZUMAB; INHIBITORS; BIOLOGICS; ABATACEPT; RITUXIMAB;

D O I：

10.5694/mja16.01287

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products and biosimilars in the pipeline. bDMARDs have excellent efficacy, especially when combined with traditional DMARDs, and a well characterised but manageable safety profile. These expanded therapeutic options have revolutionised patient care and made remission (including drug free remission) a realistic goal. Evidence of a “window of opportunity” that changes the long term phenotype of the disease has been well established, so therapy should be commenced as early as possible in the disease process and a shared care model between general practitioner and rheumatologist provides the best outcomes. While there is no cure for rheumatoid arthritis, treatment has improved to the point where many patients can achieve a normal quality of life. © 2017 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.

引用

页码：221 / +

页数：4

共 34 条

[1]

Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]

[2]

Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients [J].

Benham, Helen ;

Nel, Hendrik J. ;

Law, Soi Cheng ;

Mehdi, Ahmed M. ;

Street, Shayna ;

Ramnoruth, Nishta ;

Pahau, Helen ;

Lee, Bernett T. ;

Ng, Jennifer ;

Brunck, Marion E. G. ;

Hyde, Claire ;

Trouw, Leendert A. ;

Dudek, Nadine L. ;

Purcell, Anthony W. ;

O'Sullivan, Brendan J. ;

Connolly, John E. ;

Paul, Sanjoy K. ;

Le Cao, Kim-Anh ;

Thomas, Ranjeny .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (290)

[3]

Antibody treatments of inflammatory arthritis [J].

Brown, MA .

CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) :2943-2946

[4]

Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics A Systematic Review [J].

Chingcuanco, Francine ;

Segal, Jodi B. ;

Kim, Seoyoung C. ;

Alexander, G. Caleb .

ANNALS OF INTERNAL MEDICINE, 2016, 165 (08) :565-+

[5]

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis [J].

Dass, Shouvik ;

Vital, Edward M. ;

Emery, Paul .

EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (18) :2559-2570

[6]

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register [J].

Dixon, W. G. ;

Watson, K. ;

Lunt, M. ;

Hyrich, K. L. ;

Silman, A. J. ;

Symmons, D. P. M. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2368-2376

[7]

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].

Emery, Paul ;

Breedveld, Ferdinand C. ;

Hall, Stephen ;

Durez, Patrick ;

Chang, David J. ;

Robertson, Deborah ;

Singh, Amitabh ;

Pedersen, Ronald D. ;

Koenig, Andrew S. ;

Freundlich, Bruce .

LANCET, 2008, 372 (9636) :375-382

[8]

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy [J].

Emery, Paul ;

Vencovsky, Jiri ;

Sylwestrzak, Anna ;

Leszczynski, Piotr ;

Porawska, Wieslawa ;

Baranauskaite, Asta ;

Tseluyko, Vira ;

Zhdan, Vyacheslav M. ;

Stasiuk, Barbara ;

Milasiene, Roma ;

Rodriguez, Aaron Alejandro Barrera ;

Cheong, Soo Yeon ;

Ghil, Jeehoon .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :51-57

[9]

Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug A Randomized Clinical Trial [J].

Gottenberg, Jacques-Eric ;

Brocq, Olivier ;

Perdriger, Aleth ;

Lassoued, Slim ;

Berthelot, Jean-Marie ;

Wendling, Daniel ;

Euller-Ziegler, Liana ;

Soubrier, Martin ;

Richez, Christophe ;

Fautrel, Bruno ;

Constantin, Arnaud L. ;

Mariette, Xavier ;

Morel, Jacques ;

Gilson, Melanie ;

Cormier, Gregoire ;

Salmon, Jean Hugues ;

Rist, Stephanie ;

Liote, Frederic ;

Marotte, Hubert ;

Bonnet, Christine ;

Marcelli, Christian ;

Sellam, Jeremie ;

Meyer, Olivier ;

Solau-Gervais, Elisabeth ;

Guis, Sandrine ;

Ziza, Jean-Marc ;

Zarnitsky, Charles ;

Chary-Valckenaere, Isabelle ;

Vittecoq, Olivier ;

Saraux, Alain ;

Pers, Yves-Marie ;

Gayraud, Martine ;

Bolla, Gilles ;

Claudepierre, Pascal ;

Ardizzone, Marc ;

Dernis, Emmanuelle ;

Breban, Maxime A. ;

Fain, Olivier ;

Balblanc, Jean-Charles ;

Aberkane, Ouafaa ;

Vazel, Marion ;

Back, Christelle ;

Candon, Sophie ;

Chatenoud, Lucienne ;

Perrodeau, Elodie ;

Sibilia, Jean ;

Ravaud, Philippe .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (11) :1172-1180

[10]

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential [J].

Hamilton, John A. .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (04) :457-465

← 1 2 3 4 →